Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma - Wikidata - wikimedia - TriplyDB

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

http://www.wikidata.org/entity/Q28343226

about

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor li Molecular pathways: trafficking of metabolic resources in the tumor microenvironment Adipocytes: impact on tumor growth and potential sites for therapeutic intervention Experimental therapies and ongoing clinical trials to slow down progression of ADPKD PGC-1α, mitochondrial dysfunction, and Huntington's disease Chemotherapy and chemoprevention by thiazolidinediones Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas Activation of PPARalpha and PPARgamma by environmental phthalate monoesters The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma Adipose-derived stem cells for regenerative medicine Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice Hic-5 regulates an epithelial program mediated by PPARgamma Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition Pharmacological peroxisome proliferator-activated receptorgamma ligands: emerging clinical indications beyond diabetes.Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ Differentiation therapy of leukemia: 3 decades of development.In vivo effects of rosiglitazone in a human neuroblastoma xenograft.Energy restriction as an antitumor target of thiazolidinediones.Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.Peroxisome proliferator-activated receptors in the cardiovascular system.Insulin sensitiser drugs.A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain?Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma Controversy: PPARgamma as a target for treatment of colorectal cancer.Advances in the targeted therapy of liposarcoma.Biology and toxicology of PPARgamma ligands.Retroperitoneal liposarcoma: current insights in diagnosis and treatment Pleomorphic liposarcoma: clinical observations and molecular variables.Modified fatty acids and their possible therapeutic targets in malignant diseases.

P2860

Q24601222-384F7656-D0B9-426A-ADD8-06181E020AC4 Q24803926-8A4D6140-B9A5-4DD2-8464-37C52B86D00B Q24806395-E45973CF-A200-4646-B3CE-F8BE6258A327 Q26825620-60447737-C3A0-44D7-969A-F9827CC89119 Q26830077-BDD28D2A-7E3F-4D3C-A92B-E25F72D8D6D3 Q27001230-1442C760-4C99-45BA-B7A0-0A8944E8A81C Q27001671-20A36FCE-1ECD-414A-9FFC-CDA5C56E1E98 Q27011352-11BBA271-1D6A-4909-B757-CCC41265FA9A Q28070220-0F4B53DA-CE38-4946-B9B6-88E5B41E5C99 Q28076210-38C65511-99A7-47FE-8B23-D284B45F0792 Q28179002-BC8AE987-5384-4477-A838-2465AB0B3DA3 Q28238709-360C1E36-0C6A-4C04-8582-ECDC07CB3286 Q28251474-70D5712B-BB48-4626-8923-826C49DA0BE6 Q28301763-17BCF53D-74C4-4302-BB19-162AE3F44B86 Q28366616-815DE292-6F6B-4C86-8B23-1662BE885BDC Q28389770-6B8DC263-8CF8-4ABB-982D-0F21400B0081 Q28586821-EFF40DCD-FC66-45F1-9C02-FB4C99842A04 Q30498249-376B40C8-0BC1-4CF1-BC77-5D73A5421224 Q30977623-12B901B1-B0E5-4C7C-AA73-B8B52B35C345 Q33183686-F5EA4DE8-1DDE-408D-8258-A0F69F94A843 Q33215831-B4FAA2FB-558F-41F7-AAC6-388EA2B9DAF3 Q33278631-90D7B3C9-F768-44CA-B5D2-361606317C4D Q33317621-080DBC59-EEDB-4966-98A6-790128674C50 Q33409795-F374B686-D755-4F98-9CA5-A751FD00906C Q33723620-A104DE70-1755-4455-A2F5-130F9BDB5D94 Q33744668-27AD47FD-0317-404D-8991-2F4B686201AD Q33809071-70A69499-984A-4EBD-91B5-0CACF94E999E Q33850995-E1F6CDFB-123E-4737-91EE-EF19A16ECB05 Q34074912-2BE2F430-24D6-4991-ABB4-6E5EB630C2F2 Q34262817-35CD9745-F5C2-498A-977C-C46B8FD84364 Q34380511-0A12AC18-0D01-48B6-8859-995A2E0C0C26 Q34565656-8F5F416F-9231-4778-8FA4-907D8E59F3A2 Q34633368-6671986D-B920-4300-A397-F3FB3CFB8552 Q34635550-4A1C4B31-C02C-47BA-BBBD-1DD6613EBCC2 Q34744898-7FA4BEA3-5000-46C0-BC25-FAB326779822 Q34952133-6ED39528-AFAD-41A5-A752-929B5EC2FC44 Q34986544-CC55798E-DDB2-4985-88FD-7D59909EF259 Q35066363-6CC1020F-A88F-4392-8F23-30A7A33ABAF0 Q35179511-1572AB0B-2068-4F9A-B334-A98924CBCE63 Q35537914-A3C9D6F0-8864-4F42-876F-3BABCE214B7B

P2860

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

http://www.wikidata.org/entity/Q28343226

description

1999 nî lūn-bûn

@nan

1999 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի մարտին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Induction of solid tumor diffe ...... e in patients with liposarcoma

@ast

Induction of solid tumor diffe ...... e in patients with liposarcoma

@en

Induction of solid tumor diffe ...... e in patients with liposarcoma

@nl

type

label

Induction of solid tumor diffe ...... e in patients with liposarcoma

@ast

Induction of solid tumor diffe ...... e in patients with liposarcoma

@en

Induction of solid tumor diffe ...... e in patients with liposarcoma

@nl

prefLabel

Induction of solid tumor diffe ...... e in patients with liposarcoma

@ast

Induction of solid tumor diffe ...... e in patients with liposarcoma

@en

Induction of solid tumor diffe ...... e in patients with liposarcoma

@nl

P1433

Q28343226-77BDBA3F-4765-4F83-AF9C-96C8491FF584

P1476

Q28343226-405683E8-03D4-4538-988E-3A1426DD3571

P2093

Q28343226-07A495FA-2E44-423E-89BC-1D60B0842C98

Q28343226-32225A19-E1F5-478C-A723-A493FD9F8463

Q28343226-6DF972FE-4C88-47E4-9281-881A0695FF99

Q28343226-90CC8B10-2BF4-448A-8D48-25429305516D

Q28343226-B5DDDE34-0A28-4E0F-ABDF-8E81C39CDB90

Q28343226-CAC09EA7-2157-44D4-A718-B90D59DC3F25

Q28343226-E1EE0804-207C-4BAF-B9B2-7C85B1DF4CE5

Q28343226-FA11A560-A266-45F2-AC1D-4511C1121169

P2860

Q28343226-0AFAE65C-3BE6-4032-B7D8-2665C2C77A07

Q28343226-14049BE9-6E3D-4368-BD1D-7405E1C5E9DF

Q28343226-156F3402-512C-40E5-9E53-F9ABA049B358

Q28343226-2EC7B68A-20B4-4432-9231-E0B204D662A8

Q28343226-47072ABA-0A55-4B8E-BEF9-554733B1966B

Q28343226-51DD7791-D051-42DE-8303-334016CD304C

Q28343226-5439BD38-585C-49AE-9AB4-2E305304DDA2

Q28343226-5C31B6DF-7AC3-41E0-9805-1BEF963959ED

Q28343226-68C4CB8D-30E0-4975-8F3A-049956192F26

Q28343226-6AF287FA-91E7-4768-9C0E-D770878B59D0

P304

Q28343226-CB06D603-17C3-478B-A23D-F78D98128F19

P31

Q28343226-A438B1EB-0402-4E48-BCCD-DA76ADD23AD3

P3181

Q28343226-A5BC55BB-B840-42A7-9FE0-033F8497439A

P356

Q28343226-2867BFA2-2B64-40E9-87B3-6CA4793ED2D9

P407

Q28343226-0DA1A4B1-2C88-4E3C-9914-A69B2B0E3403

P433

Q28343226-5A3FBC67-C662-43E8-98F7-B060F166AC94

P478

Q28343226-E502FAE7-1E32-439E-99C0-FADC3D29D687

P577

Q28343226-9E38F0C3-3458-419A-9356-BACF1CDB8407

P5875

Q28343226-4E9B599E-5343-40D1-BBED-DDE58F530018

P698

Q28343226-31BD6ABC-CF17-4AA3-A6FD-5407FCCEC00D

P921

Q28343226-34F01153-05C3-4423-942F-74BD0773B082

P932

Q28343226-38A3B799-4F84-476C-A215-B701BAC03D52

P3181

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Induction of solid tumor diffe ...... e in patients with liposarcoma

@en

P2093

B M Spiegelman

http://www.w3.org/2001/XMLSchema#string

C D Fletcher

http://www.w3.org/2001/XMLSchema#string

E Mueller

http://www.w3.org/2001/XMLSchema#string

G D Demetri

http://www.w3.org/2001/XMLSchema#string

N Campbell

http://www.w3.org/2001/XMLSchema#string

P Sarraf

http://www.w3.org/2001/XMLSchema#string

R Naujoks

http://www.w3.org/2001/XMLSchema#string

S Singer

http://www.w3.org/2001/XMLSchema#string

P2860

Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma

Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha

Differential expression and activation of a family of murine peroxisome proliferator-activated receptors

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis.

Myxoid liposarcoma. Experience with chemotherapy.

P304

3951-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3037892

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.96.7.3951

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13194346

http://www.w3.org/2001/XMLSchema#string

P698

10097144

http://www.w3.org/2001/XMLSchema#string

P921

P932

22401

http://www.w3.org/2001/XMLSchema#string